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INTRODUCTION
In the last decade, a matched unrelated donor (URD)
has become an increasingly effective source of stem cells for
transplantation for patients without a family donor [1,2]. In
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ABSTRACT
High incidences of graft failure, graft-vs.-host disease (GVHD), and serious infections following unrelated donor
(URD) marrow transplantation, despite apparent human leukocyte antigen (HLA) identity, may reflect the presence
of molecular disparities, including those for HLA-C alleles between the patient and the URD. The level of these
disparities could be significant, because as many as 42 alleles are currently known for HLA-C locus. We studied 84
patients and 251 potential URDs to evaluate 1) the extent of HLA-C disparity between the patient and the URD
identified by serology for HLA-A and -B and by DNA typing for -DRB1 and 2) the level of HLA-C disparity
between patients and URDs matched by high-resolution DNA typing for HLA-A, -B, and -DRB1. The DNA typing
was performed at the Memorial Sloan Kettering Cancer Center, and the serotyping was provided by the registries.
Of 251 URDs matched by HLA-A and -B serology and -DRB1 (sA_sB_dnaDRB1); 94, 75, and 82 were 6/6, 5/6, and
4/6 matches, respectively. Of 94 sA_sB_dnaDRB1 6/6 URDs, 51 (54.3%) were matched for both HLA-C alleles. In
contrast, 31 (41.3%) 5/6 (p 5 0.12) and 15 (18.3%) 4/6 (p , 0.01) sA_sB_dnaDRB1 URDs were matched for both
HLA-C alleles. Following DNA typing for HLA-A and -B, 52 (55.3%) of 94 6/6, 30 (40%) of 75 5/6, and 25 (30.5%)
of 82 4/6 sA_sB_dnaDRB1 URDs remained 6/6, 5/6, and 4/6 matches at the DNA level (dnaA_B_DRB1). HLA-C
disparities continued to exist in the dnaA_B_DRB1 URD group. Of 54 dnaA_B_DRB1 6/6 URDs, 41 (75.9%) were
matched for both HLA-C alleles. Only 45.3% of the 5/6 (p 5 0.01) and 22.2% of the 4/6 (p , 0.01) dnaA_B_DRB1
URDs were matched for both HLA-C alleles. In the 6/6 category, the frequency of HLA-C matching improved
(75.9 vs. 54.3%; p 5 0.01) following DNA matching for HLA-A and -B. In comparison to mismatching for HLA-B
locus, mismatching for either HLA-DRB1 or -A resulted in a lower odds ratio for HLA-C disparity. The presence of
a common haplotype in the sA_sB_dnaDRB1 (p 5 0.06) URD category improved the level of HLA-C matching. We
identified alleles that are associated with high (B*1501, B*4402, B*5101, DRB1*0101, A*0201, A*1101, A*2301, and
A*3201) or low (B*0702, B*0801, B*1302, B*3502, DRB1*0301, DRB1*1104, A*0101, A*3001, and A*6801) proba-
bility of HLA-C disparity. Overall, sA_sB_dnaDRB1 as well as dnaA_B_DRB1 matched URDs for non-Caucasian
patients were more likely to have HLA-C disparity in comparison to the matched URDs of Caucasian patients.
However, a high incidence of HLA-C disparities was identified even in the URDs for Caucasian patients. Whether
the disparities demonstrated by this study contribute to the higher immunological complications noted following
URD bone marrow transplantation is unclear. Outcome analysis and studies aimed at understanding the functional
role of HLA-C may provide an answer.
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addition, because of the tremendous growth of national and
international donor registries, the number of URD stem cell
transplants has increased during this period [1–5]. Concur-
rently, there has also been a consistent improvement in the
outcome of URD transplants [6–10]. Despite these gains,
the incidences of immunological complications (including
graft-vs.-host disease [GVHD], graft rejection, and delayed
immune reconstitution, leading to potentially life-threaten-
ing infections) continue to be far more severe and frequent
following URD–bone marrow transplantation (BMT)
[8,11–13]. The difference in outcomes between  sibling
donor and URD transplantations may reflect the presence
of genotypic disparities between the patients and the URDs
that remain undetected by conventional HLA typing using
serology for HLA-A and -B and DNA typing for -DRB1.
The siblings who match for HLA-A, -B, and -DR by con-
ventional testing (and who are, therefore, phenotypically
identical), are very likely to be genotypically identical
because of the inheritance of haplotypes comprising the
whole HLA complex from the parents [14]. Because recom-
bination within the HLA complex is rare [14], the family
donors are also likely to have allelic identity within the HLA
complex at loci other than HLA-A, -B, and -DR. In con-
trast, a patient–URD pair that matches for HLA-A and -B
by serology and for HLA-DRB1 by the DNA typing may be
genotypically disparate as a result of the presence of molec-
ular variant disparities at HLA-A and/or HLA-B loci at the
allelic level; and disparities at HLA loci other than HLA-A,
-B, and -DRB; or both. We have recently shown that geno-
typic disparities at the HLA-A and -B loci do exist between
serologically matched patient–URD pairs and that DNA
typing can elucidate these disparities [15]. However, DNA
typing for HLA-A and -B may not assure genotypic match-
ing for other alleles within the HLA complex. Recent labo-
ratory and clinical data indicate that HLA-C plays a more
significant role in alloreactions and BMT than previously
suspected [16–23]. With 42 known alleles [24], HLA-C is a
highly polymorphic locus. Therefore, it would not be sur-
prising if significant disparity for HLA-C were to be found
between patients and otherwise matched URDs. In the past,
the significance of HLA-C in alloreactions affecting the out-
come of marrow transplants was not studied. Analyses were
hindered by technical difficulties, including the existence of
multiple alleles constituting as many as 30–45% of the total
that could not be typed by serology and were reported as
“blanks” [25]. Evaluation of HLA-C disparities and their
significance has now become possible with the development
of DNA typing methods for class I loci [17,26–28].
In this study we have applied novel, highly discriminato-
ry molecular techniques in a large cohort to identify at the
DNA level the HLA-C disparities between patients and
their potential URDs who were also molecularly typed for
HLA-A, -B, and -DRB1. Our aims were as follows: a) to
identify the extent and the pattern of HLA-C genotypic dis-
parities existing between patient–URD pairs matched by
conventional typing (HLA-A and -B serology and DNA
typing for HLA-DRB1); b) to examine if the selection of
URDs based on matching for HLA-A, -B, and -DRB1 by
DNA typing has any impact on the incidence or degree of
HLA-C disparity; c) to analyze the influence of individual
matching for HLA-A, -B, and -DRB1 loci on the level of
HLA-C genotypic disparity; d) to determine if the level of
HLA-C disparity in patient–URD pairs expressing one of
the commonly observed haplotypes is different from pairs
without these common haplotypes; and e) to determine the
influence of the race/ethnicity of the patients on the fre-
quency of HLA-C disparity.
MATERIALS AND METHODS
The study was conducted between July 1996 and Feb-
ruary 1998, at the Memorial Sloan Kettering Cancer Cen-
ter (MSKCC), New York. During the study period, 84
patients and 251 potential URDs were identified and typed
by high-resolution DNA typing for HLA-A, -B, -C, and -
DRB1. By HLA-A and HLA-B serology and sequence-spe-
cific oligonucleotide probe (SSOP) analysis of HLA-DRB1
(sA_sB_dnaDRB1), 94 URDs were 6/6, 75 were 5/6, and 82
were 4/6 matches. Following DNA typing for HLA-A and -
B (dnaA_B_DRB1), 52 of 94 (55.3%) originally 6/6 URDs
remained 6/6. Of 75 5/6 and 82 4/6 sA_sB_dnaDRB1
URDs, 30 (40%) and 25 (30.5%) remained 5/6 and 4/6
DNA matches, respectively. Fifty-seven of 84 patients self-
reported as Caucasians. A total of 182 URDs were selected
for 57 Caucasian patients. The remaining 69 URDs were
selected for 27 non-Caucasian patients (Hispanic, 10;
African-American, 8; Asian, 8; others, 1). The cohort of
URDs selected for Caucasian patients will be called
“ptCAUC” and those selected for non-Caucasian patients
will be called “ptNonCAUC.”
Typing technique
The DNA typing for HLA-A, -B, -C, and -DRB1 alleles
for the patients and URDs were conducted at our center.
The serological typing on the URDs was provided by the
registries. Our pilot studies to evaluate the need for re-
serotyping all samples from URDs indicated that this expen-
sive and time-consuming testing was unnecessary. Level of
discrepancy was very low. In addition, we have recently
demonstrated that after DNA typing, less than 2% of URDs
were identified as having HLA-A and -B alleles outside of
their registry-defined serotypes [29]. URDs who matched
for World Health Organization (WHO)–defined “split”
antigens [30] were considered serological matches. DNA
typing for HLA-A, -B, and -C was performed by SSOP, as
previously described [29,31], and HLA-DRB1 typing was
performed according to the well-established protocol [32].
Alleles were assigned according to the DNA sequences pub-
lished by the WHO committee [30]. The nucleated cells
from the blood samples were collected, and genomic DNA
was isolated [28]. PCR amplification of the full length of
exons 2 and 3 of the HLA-A, -B, and -C genes from the
genomic DNA was performed using primers derived from
introns 1 and 3. The PCR product was dot-blotted on nylon
membrane and then cross-linked by ultraviolet light. The
membranes were hybridized with digoxigenin-
ddUTP–labeled oligonucleotide probes. After washing, the
membranes were treated with anti-digoxigenin-Fab anti-
body conjugated to alkaline phosphatase and were then
sprayed with Lumiphos 480 (Boehringer Mannheim, Ger-
many) and exposed to photographic film. We used a panel of
44, 52, and 44 probes for the HLA-A, -B, and -C loci,
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respectively. The probes were designed from the sequences
of exons 2 and 3. A locally developed computer program
analyzed the hybridization pattern for each sample and
assigned alleles. The results were checked and confirmed
manually. Heterozygotes were identified by the presence of
two different hybridization score patterns.
Data analysis and statistics
URDs were stratified according to the degree of 
matching by HLA-A, -B serology, and HLA-DRB1
(sA_sB_dnaDRB1) into 6/6, 5/6, and 4/6 groups. A sub-
group of URDs was found to be matched for HLA-A, -B,
and -DRB1 by DNA typing (dnaA_B_DRB1). Following
DNA typing for HLA-C, URDs were classified as HLA-C –
matched (matched for both HLA-C alleles) or HLA-C–mis-
matched (mismatched for one or both HLA-C alleles). All
tests of no association between categorical variables, includ-
ing the frequency of HLA-C disparity, were computed using
Fisher’s exact test.
RESULTS
HLA characteristics of patients and URDs
A total of 22 HLA-C alleles were identified in our
patient cohort, of which Cw*0401 was the most common
(Fig. 1). In comparison to the two published reports on the
Caucasoid population of Europe [33,34], the frequency of
the HLA-C alleles in our patients revealed one notable dif-
ference. Cw*0401 occurred with a frequency of 18.5% in
our patients, compared with 10–12% in the European stud-
ies [33,34]. Of the 84 patients, 8 (9.5%) were found to be
homozygous for HLA-C locus following family studies. One
allele in 30 of 84 patients (35.7%) and both alleles in two
patients (2.4%) belonged to the serologically “blank” cate-
gory. Of the serologically blank HLA-C alleles, Cw*1203
was the most common. A total of 29 HLA-A, 45 HLA–B,
and 37 HLA-DRB1 alleles were observed (Table 1). A*0201,
B*0702, and DRB1*0701 were the most common alleles
within the respective loci. Following DNA typing, 2.1% of
HLA-A and 2.8% of HLA-B alleles were found to be out-
side the serological group they were assigned by the Nation-
al Marrow Donor Program or other registry.
HLA-C matching: sA_sB_dnaDRB1 vs. dnaA_B_DRB1
HLA-C disparity for one allele between the patient
and URD was seen in 37 of the 94 (39.4%) 6/6
sA_sB_dnaDRB1 URDs. Six (6.4%) URDs were disparate
for both HLA-C alleles. The remaining 51 (54.3%) 6 of 6
sA_sB_dnaDRB1 URDs were matched at both HLA-C
alleles. Compared with the 6/6 sA_sB_dnaDRB1 category,
the level of HLA-C disparity was significantly higher (Fig.
2a) within the 4/6 (p , 0.01) sA_sB_dnaDRB1 URD cate-
gory. In addition, the level of HLA-C disparity was higher
within the 4/6 compared with the 5/6 (p , 0.01)
sA_sB_dnaDRB1 URDs. However, the difference in the
level of HLA-C disparity between 6/6 and 5/6
Figure 1. Frequency of the occurrence of HLA-C alleles in the patient population depicted as percentages
Each column represents one HLA-C allele. Alleles belonging to each serogroup are placed together. The alleles that give a “blank” reaction on serological testing are
grouped at the right end of the graph.
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sA_sB_dnaDRB1 URDs (45.7 vs. 58.7%) was not as
strong (p 5 0.12). HLA-C disparities continued to exist
despite matching for HLA-A and -B by DNA typing. Of
54 6/6 dnaA_B_DRB1 URDs, 12 (22.2%) and one (1.9%)
were found to be mismatched for one or both HLA-C
alleles, respectively. The level of HLA-C disparity was
higher in 5/6 (p 5 0.08) and 4/6 (p , 0.01)
dnaA_B_DRB1 subsets (Fig. 2b). In addition, the level of
HLA-C disparity was higher within the 4/6 compared
with the 5/6 (p , 0.01) dnaA_B_DRB1 URDs. The level
of HLA-C disparity between sA_sB_dnaDRB1 and
dnaA_B_DRB1 within each matching category (6/6, 5/6,
and 4/6) was compared to determine if URD matching by
DNA typing for HLA-A and -B improves the level of
HLA-C matching (Table 2). A higher percentage of 6/6
dnaA_B_DRB1 URD were matched for both HLA-C alle-
les in comparison with 6/6 sABdnaDRB1 URDs (75.9 vs.
54.3%; p 5 0.01). Overall, dnaA_B_DRB1 URDs were
found to have significantly less (p , 0.01) HLA-C dispari-
ty than the sA_sB_dnaDRB1 URDs. The differences
Table 1. Frequency of HLA-A, -B, and –DRB1 alleles in the patient population
HLA-A allele Frequency (%) HLA-B allele Frequency (%) HLA-DRB1 allele Frequency (%)
A*0201 17.86 B*0702 10.12 DRB1*0701 11.90
A*0301 11.90 B*3501 6.55 DRB1*1501 9.52
A*2402 11.31 B*1801 5.95 DRB1*1101 8.93
A*0101 8.93 B*5101 5.95 DRB1*1104 7.74
A*2601 5.95 B*0801 5.36 DRB1*0301 7.74
A*1101 4.76 B*4402 5.36 DRB1*0101 5.95
A*6801 4.76 B*1302 4.17 DRB1*1301 4.76
A*3201 2.98 B*1402 4.17 DRB1*1302 3.57
A*3303 2.98 B*1501 4.17 DRB1*0102 2.98
A*0205 2.38 B*4001 3.57 DRB1*1001 2.38
A*2301 2.38 B*3503 2.98 DRB1*1103 2.38
A*3001 2.38 B*4403 2.98 DRB1*1401 2.38 
A*3002 2.38 B*5301 2.98 DRB1*1503 2.38 
A*3101 2.38 B*5801 2.98 DRB1*0402 2.38 
A*0202 1.79 B*1503 2.38 DRB1*1402 1.79 
A*0217 1.79 B*3502 2.38 DRB1*1502 1.79 
A*2901 1.79 B*3801 2.38 DRB1*0401 1.79 
A*6802 1.79 B*4002 1.79 DRB1*0404 1.79 
A*0204 1.19 B*4901 1.79 DRB1*0407 1.79 
A*0206 1.19 B*1516 1.19 DRB1*0804 1.79 
A*0207 1.19 B*2702 1.19 DRB1*0901 1.79 
A*2902 1.19 B*3512 1.19 DRB1*1304 1.19 
A*3301 1.19 B*4006 1.19 DRB1*1305 1.19 
A*0302 0.60 B*5001 1.19 DRB1*1601 1.19 
A*2501 0.60 B*5201 1.19 DRB1*0403 1.19 
A*2602 0.60 B*5501 1.19 DRB1*0411 1.19 
A*6602 0.60 B*5701 1.19 DRB1*1201 0.60 
A*6901 0.60 B*5703 1.19 DRB1*1202 0.60 
A*7401 0.60 B*0705 0.60 DRB1*1303 0.60 
Total 100.00 B*1301 0.60 DRB1*1312 0.60 
B*1517 0.60 DRB1*1403 0.60 
B*1518 0.60 DRB1*1405 0.60 
B*15N 0.60 DRB1*1602 0.60 
B*1803 0.60 DRB1*0405 0.60 
B*2705 0.60 DRB1*0406 0.60 
B*2707 0.60 DRB1*0801 0.60 
B*3505 0.60 DRB1*0803 0.60 
B*3508 0.60 Total 100.00 
B*3701 0.60 
B*3901 0.60 
B*4101 0.60 
B*4102 0.60 
B*4201 0.60 
B*4701 0.60 
B*4801 0.60 
B*51N 0.60 
B*7801 0.60 
Total 100.00
Patient number, 84; allele number, 84 3 2 5 168.
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within the 5/6 and 4/6 categories were not significant (p 5
0.19 for 5/6 and p 5 1.0 for 4/6).
Effect of matching for HLA-A, -B, and -DRB1 loci
individually
The effect of genotypic matching for HLA-A, -B, and -
DRB1 loci individually on the level of HLA-C disparity was
determined (Table 3). The URDs (n5251) were stratified for
HLA-A, -B, and -DRB1 matching as follows: MA, matched
for both HLA-A alleles (n5171); MMA, mismatched for
HLA-A alleles (n580); MB, matched for both HLA-B alleles
(n5121); MMB, mismatched for HLA-B alleles (n5130);
MDRB1, matched for both HLA-DRB1 alleles (n5114); and
MMDRB1, mismatched for HLA-DRB1 alleles (n5137).
Within the MA group, 77 of 171 (45.1%) were matched for
both HLA-C alleles, compared with 20 of 80  (25%) URDs
within the MMA group (p , 0.01; odds ratio 5 2.46). In the
MB group, 67 of 121 (55.4%) were matched for HLA-C,
whereas in the MMB group, 30 of 130 (23.1%) URDs were
matched for both HLA-C alleles (p , 0.01; odds ratio 5
4.14). Within the MDRB1 group, 56 of 114 (49.1%),  and in
the MMDRB1 group, 41 of 137 (29.9%) URDs were
matched for both HLA-C alleles (p , 0.01; odds ratio 5
2.26). Further analysis of the patients and their matched
URDs led to the identification of HLA-B, -DRB1, and -A
alleles that are associated with high risk and others with low
risk of HLA-C disparity. We define high risk and low risk as
observing greater than 2:1 odds for HLA-C mismatching
and matching, respectively. For example, all HLA-
A–matched URDs were stratified into HLA-C–matched and
HLA-C–mismatched subgroups. The frequency of occur-
rence of various HLA-A alleles was then compared between
the two subgroups. The HLA-A alleles observing greater
than 2:1 odds for HLA-C matching (low risk) and HLA-C
mismatching (high risk) were identified. The matched URDs
expressing B*0702, B*0801, B*1302, B*3502, DRB1*0301,
DRB1*1104, A*0101, A*3001, and A*6801 were at low risk
for HLA-C disparity. In contrast, matched URDs with
Figure 2. Level of HLA-C genotype identified in (A) conventionally matched (sA_sB_dnaDRB1) and (B) DNA matched (dnaA_B_DRB1) URDS 
Each column represents the HLA-A, -B, and -DRB1 matching status of the unrelated donor (URD) (6/6, 5/6, and 4/6). The blocks within each column represent
the level of HLA-C matching. The number of URDs in each category is shown within the columns and the percentage values are next to the column. (A) Com-
pared with the 6/6 sA_sB_dnaDRB1 category, the level of HLA-C disparity was significantly higher within the 4/6 (p , 0.01) sA_sB_dnaDRB1 URD category.
In addition, the level of HLA-C disparity was higher within the 4/6 compared with the 5/6 (p , 0.01) sA_sB_dnaDRB1 URD. However, the difference in the
level of HLA-C matching between 6/6 and 5/6 sA_sB_dnaDRB1 URDs (54.3 vs. 41.3%; p 5 0.12) was not as strong. (B) Compared with the 6/6
dnaA_B_DRB1 category, the level of HLA-C disparity was higher in the 5/6 (p 5 0.08) and the 4/6 (p , 0.01) dnaA_B_DRB1 subsets. In addition, the level of
HLA-C disparity was higher within the 4/6 compared with the 5/6 (p , 0.01) dnaA_B_DRB1 category.
A B
Table 2. Comparison of the level of HLA-C disparity between sA_sB_dnaDRB1 and dnaA_B_DRB1 within each matching categorya
Match criteria for Number of HLA-C match HLA-C mismatch 
HLA-A, -B, and -DRB1 URDs n (%) n (%) p
6/6 sA_sB_dnaDRB1 94 51 (54.3) 43 (45.7)
0.01
dnaA_B_DRB1 54 41 (75.9) 13 (24.1)
5/6 sA_sB_dnaDRB1 75 31 (41.3) 44 (58.7)
0.19
dnaA_B_DRB1 30 17 (56.7) 13 (43.3)
4/6 sA_sB_dnaDRB1 82 15 (18.3) 67 (81.7)
1.0
dnaA_B_DRB1 25 5 (20.0) 20 (80.0)
All sA_sB_dnaDRB1 251 97 (38.6) 154 (61.4)
,0.01
dnaA_B_DRB1 109 63 (57.8) 46 (42.2)
aMatching categories include 6/6, 5/6, and 4/6.
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B*1501, B*4402, B*5101, DRB1*0101, A*0201, A*1101,
A*2301, and A*3201 were at high risk.
The influence of common haplotypes
Haplotypes were assigned for 59 of 84 patients by family
typings. Of 251 URDs, 188 had been selected for these 59
patients. Fifteen patients carried one of the 10 most com-
mon serologically defined haplotypes (A1B8DR3,
A2B7DR15, A2B15DR4, A2B44DR4, A2B50DR7,
A2B51DR13, A3B7DR15, A24B35DR11, A29B44DR7, and
A30B13DR7) [25]. None of the patients had two of the
above haplotypes. A total of 55 URDs had been selected for
these 15 patients by original typing (sA_sB_dnaDRB1). The
URDs for these patients made up the common haplotype
(CH)–sA_sB_dnaDRB1 subgroup, and the URDs (n5133)
identified for the rest of the patients (n544) constituted the
NoCH–sA_sB_dnaDRB1 group. Both of the groups were
further stratified according their original typing status into
6/6, 5/6, and 4/6 subgroups. The level of donor–recipient
genotypic disparity was lower in the CH–sA_sB_dnaDRB1
group in comparison to the NoCH–sA_sB_dnaDRB1 group
(n50.06). The interpretation of the differences in the level
of HLA-C disparity between CH–sA_sB_dnaDRB1 and
NoCH–sA_sB_dnaDRB1 URDs within 6/6, 5/6, and 4/6
subgroups was limited because of small numbers within
individual subgroups.
Effect of patient ethnicity/race
Of 182 ptCAUC URDs, 80, 56, and 46 were 6/6, 5/6,
and 4/6 matches by original typing (sA_sB_dnaDRB1; Table
4). Of 69 ptNonCAUC URDs, 14, 19, and 36 were 6/6, 5/6,
and 4/6 matches by original typing. The percentage of
URDs with HLA-C disparity was significantly higher in the
“ptNonCAUC” compared with the ptCAUC URDs (75.4
vs. 56.0%; p , 0.01). Because of the small sample size, dif-
ferences between ptCAUC and ptNonCAUC
sA_sB_dnaDRB1 URDs were not significant in the 6/6 (p 5
0.39), 5/6 (p 5 0.78), and 4/6 (p 5 0.16) matching subcate-
gories. Similar analysis was carried out for the URDs
matched by DNA typing for HLA-A, -B, and -DRB1
(dnaA_B_DRB1). The ptCAUC group contained 50 6/6, 49
5/6, and 48 4/6 and the ptNonCAUC group had 4 6 /6, 15
5/6, and 24 4/6 dnaA_B_DRB1 matched URDs. Again, in
the dnaA_B_DRB1 group, the percentage of URDs with
HLA-C disparity was significantly higher in the ptNon-
CAUC compared with the ptCAUC URDs (72.1 vs. 49.7%;
p 5 0.01). The differences between ptCAUC and ptNon-
CAUC dnaA_B_DRB1 URDs were not significant in the
6/6 (p 5 0.56) and 5/6 (p 5 0.56) subgroups, potentially due
to small numbers of ptNonCAUC URDs within the sub-
groups.
DISCUSSION
We have recently shown that the use of serologic typing
for HLA-A and -B results in HLA-A and -B disparities in
47% of 6/6 matched patient–URD pairs [15]. In this study we
demonstrate that HLA-C disparities exist between many
patients and their conventionally matched (sA_sB_dnaDRB1)
or DNA–matched (dnaA_B_DRB1) URD. Although HLA-C
Table 3. Effect of DNA matching for HLA-A, -B, and -DRB1 alleles on the level of HLA-C matching
Both HLA-C allele One HLA-C allele Both HLA-C allele Total number Comparison 
Allele match/mismatch match [n (%)] mismatch [n (%)] mismatch [n (%)] of URDs parameter p Odds ratio
Matched for both -A (MA) 77 (45.0) 76 (44.4) 18 (10.5) 171
MA vs. MMA ,0.01 2.46
Mismatched for -A (MMA) 20 (25.0) 45 (56.25) 15 (18.75) 80
Matched for both -B (MB) 67 (55.4) 51 (42.1) 3 (2.5) 121
MB vs. MMB ,0.001 4.14
Mismatched for -B (MMB) 30 (23.1) 70 (53.8) 30 (23.1) 130
Matched for both -DRB1 (MDRB1) 56 (49.12) 47 (41.23) 11 (9.65) 114
MDRB1 vs. MMDRB1
Mismatched for -DRB1 (MMDRB1) 41 (29.9) 74 (54.0) 22 (16.1) 137 ,0.01 2.26
Table 4. Effect of ethnicity/race of the patients on the level of HLA-C disparity between patient–URD pairs matched by serology for HLA-A and -B and DNA
typing for HLA-DRB1(sA_sB_dnaDRB1) as well as between pairs matched by DNA typing for HLA-A, -B, and -DRB1 (dnaA_B_DRB1)
HLA-A, -B, and -DRB1 sA_sB_dnaDRB1 URD dnaABDRB1 URD
matching HLA-C match Mismatch HLA-C match Mismatch
status [n (%)] [n (%)] Total p [n (%)] [n (%)] Total p
6 of 6 ptCauc 45 (56.3) 35 (43.8) 80
0.40
37 (74.0) 13 (26.0) 50
0.56
ptNonCauc 6 (42.9) 8 (57.1) 14 4 (100) 0 (0.0) 4
5 of 6 ptCauc 24 (42.9) 32 (57.1) 56
0.79
21 (42.9) 28 (57.1) 49
0.56
ptNonCauc 7 (36.8) 12 (63.2) 19 8 (53.3) 7 (46.7) 15
4 of 6 ptCauc 11 (23.9) 35 (76.1) 46
0.16
16 (33.3) 32 (66.7) 48
,0.01
ptNonCauc 4 (11.1) 32 (88.9) 36 0 (0) 24 (100) 24
All URDs ptCauc 80 (44.0) 102 (56.0) 182
,0.01
74 (50.3) 73 (49.7) 147
0.01
ptNonCauc 17 (24.6) 52 (75.4) 69 12 (27.9) 31 (72.1) 43
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matching is not a part of current criteria for selecting stem
cell donors, the guidelines may change in view of growing
evidence of the importance of HLA-C in clinical stem cell
transplantation. Recent clinical reports suggest that a
donor–recipient mismatch at the HLA-C locus may be asso-
ciated with GVHD [20,23], marrow graft rejection [20,22],
and renal transplant rejection [35]. In a recent Japanese
report, HLA-C mismatching was associated with a high risk
(p 5 0.001) of grade III–IV acute GVHD [23]. In addition,
the authors observed a slightly higher incidence of relapse in
HLA-C matched recipients (p 5 0.06). Although the findings
are noteworthy, they should not be extrapolated to a much
more ethno-racially mixed U.S. population. The level of
HLA-C disparity identified in our study confirms and extends
that reported by a European group who examined 73 patients
and 184 potential matched URDs selected by serology for
HLA-A and -B and DNA typing for -DRB1 [17]. The level
of HLA-C disparity in the Japanese study was lower than that
seen by us. In the present study, we additionally determined
that HLA-C disparities continue to exist, although to a lesser
extent, despite DNA typing for HLA-A and -B. In addition,
fewer than 6 of 6 HLA-A, -B, and -DRB1 match either by
serology or by DNA typing results in a tendency towards
worse HLA-C matching.
The indicators of the probability of HLA-C matching
that we have identified in this study may be of use until
HLA-C matching by DNA typing is accepted as a criteria
for URD selection. Because the odds ratio of HLA-C
matching in B-mismatched URDs is higher in comparison
to either A- or DRB1- mismatched URDs, it is likely that
when selecting a partially mismatched URD, matching for
HLA-B may be preferable to matching at either of the other
two loci. In a separate study, we not only established the
presence of a strong linkage disequilibrium (LD) between
HLA-B and -C loci at the allelic level, but also determined
the probability of HLA-C matching between two unrelated
individuals who match for both -B alleles (36). The determi-
nations were made for most of the common HLA-B alleles
seen in our population. With the above approach, one is less
likely to select an HLA-C–mismatched URD. Furthermore,
information about the high-risk alleles like B*1501, B*4402,
B*5101, DRB1*0101, A*0201, A*1101, A*2301, and A*3201;
and low-risk alleles like B*0702, B*0801, B*1302, B*3502,
DRB1*0301, DRB1*1104, A*0101, A*3001, and A*6801
may be of value when DNA typing for HLA-C is unavail-
able for all patients and URDs. HLA-C typing should be
directed toward the patients and URDs who carry one or
more high-risk HLA-A, -B, or -DRB1 allele. An important
finding in our study is that patients who carry a commonly
occurring haplotype are less likely to have HLA-C disparity.
This observation was made in the serologically matched
URD and reflects LD between HLA-C and other loci at the
allelic level. It is interesting that HLA-A1B8DR3, the most
common haplotype in the United States, is strikingly
unique. Following DNA typing for HLA-A and -B, all
HLA-A1 and HLA-B8 serotypes in the present and in a pre-
vious study [15] remained A*0101 and B*0801, respectively.
Therefore, all sero-matched URDs with these serotypes
remained DNA matches at HLA-A and -B. Furthermore,
B*0801 demonstrates a very strong LD with Cw*0701. In a
study of 849 individuals with known haplotypes, all B*0801
were seen in association with Cw*0701 [36]. It is therefore
very likely that a seromatched HLA-A1B8DR3 URD will be
DNA matched for HLA-A and -B, as well as -C alleles.
A large cohort of patients and URDs with alleles from a
majority of the known HLA-A, -B, -C, and -DR serological
groups suggests that these data represent a fair cross-section
of the population. Although most of the HLA-A, -B, and 
-DR haplotypes common in the Caucasian population were
represented (A1B8DR3, A3B7DR2, A2B62DR4, and
more), haplotypes that are comparatively more common in
Asian (A24B52DR2) and African-Americans (A30B42DR3)
[25,37] were also seen in our cohort, suggesting a mixed
ethnic background of the study population. Our analysis of
the patient’s ethnic/racial background on the level of HLA-
C disparity revealed two important points. First, there was a
high incidence of HLA-C disparity in URDs for Caucasian
as well as non-Caucasian patients. As many as 43.8% of 6/6
sA_sB_dnaDRB1 and 25.4% of dnaA_B_DRB1 URDs for
Caucasian patients showed HLA-C disparities. Second, the
overall level of HLA-C disparities was higher if patients
were non-Caucasians rather than Caucasians, irrespective of
the typing methodology used for HLA-A and -B (p , 0.01
for sA_sB_dnaDRB1; p 5 0.01 for dnaA_B_DRB1). The
difference in the level of HLA-C disparity between
ptCAUC and ptNonCAUC URDs was not significant when
the 6/6 or 5/6 subgroups were analyzed separately. High
HLA-C disparity in Caucasians reflects wide ethno-geo-
graphic origin of the Caucasian population of the United
States. However, it must be remembered that these observa-
tions may be influenced by bias arising from voluntary and
self-reported racial designations.
Although we clearly demonstrate the presence of a high
incidence of HLA-C disparities at the DNA level in HLA-
matched patient–URD pairs, the clinical significance of
these disparities has as yet not been conclusively proven. We
hope that future clinical studies will further illustrate the
importance of HLA-C in BMT. If such studies confirm a
correlation between HLA-C matching and transplant out-
come, HLA-C matching by DNA typing may be recom-
mended for URD selection, especially if multiple URDs are
available. One may argue that inclusion of HLA-C as a
matching criterion will limit the number of available donors.
Our own analysis offers encouraging results. For 40.9% (9
of 22) patients with more than one 6/6 URD, 40.9% (9 of
22) with more than one 5/6 URDs, and 56.5% (13 of 23)
with more than one 4/6 URD, a better HLA-C match was
available within our cohort of URDs. Our observation sug-
gests that finding a better HLA-C match within the HLA-
A–, -B–, and -DRB1–matched URD identified by current
registries is possible.
In the last few years, HLA-C has been increasingly rec-
ognized by a number of laboratory investigators to play an
important immunological role in regulating the cytotoxic
activity of natural killer (NK) cells in their interactions with
hemopoietic cells. The engagement of killer inhibitory
receptors on NK cells by self-type HLA-C gene products
on the target cells can inhibit NK cell-mediated cytotoxicity.
Indeed, HLA-C has been identified as the critical self-iden-
tifying ligand that protects targets from lysis by allodiscrimi-
natory NK cells [38–44]. Given the role played by NK cells
as the mediators of GVHD and graft rejection [45,46], it is
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likely that HLA-C may be an important determinant of
BMT outcome. Analyses of the results of transplants
between HLA-C–disparate individuals coupled with an
improved understanding of the role of HLA-C in
donor–host cell interactions will define whether and to what
degree the routine use of HLA-C typing by DNA methods
improves selection of an appropriate URD.
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